Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
Open Access
- 12 March 1999
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 79 (11-12), 1742-1745
- https://doi.org/10.1038/sj.bjc.6690277
Abstract
The purpose of the study was to determine prognostic significance of pretreatment serum levels of different molecules involved in cell to cell interactions along with other clinical parameters in patients with metastatic renal cell carcinoma. sICAM-1, sVCAM-1 and sELAM-1 serum levels were determined by ELISA assays in sera from 99 patients with histologically confirmed progressive metastatic renal cell carcinoma prior to initiation of systemic therapy. Kaplan–Meier survival analysis, log-rank statistics and two-proportional Cox regression analyses were employed to identify risk factors and to demonstrate statistical independence. In univariate analyses, the following pretreatment risk factors could be identified: serum sICAM-1 level > 360 ng ml–1, erythrocyte sedimentation rate > 70 mm h–1, serum C-reactive protein level > 8 mg l–1, serum lactic dehydrogenase level > 240 U/ l and neutrophil count > 6000 μl–1. Multivariate analyses demonstrated statistical independence for serum sICAM-1 level, erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level as pretreatment predictors of overall patient survival. The prognostic significance of sICAM-1 might indicate a role of this molecule for tumour progression, potentially in association with the abrogation of anti-tumour immune responses. The possibility of defining a pretreatment risk model based on sICAM-1 level, ESR and CRP also warrants further investigation, with regard to a possible linkage between acute phase proteins and sICAM-1 levels.Keywords
This publication has 34 references indexed in Scilit:
- Elevated serum levels of soluble ICAM‐1 in non‐Hodgkin’s lymphomas correlate with tumour burden, disease activity and other prognostic markersBritish Journal of Haematology, 1996
- Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasiaEuropean Journal Of Cancer, 1995
- Serum acute phase reactants and prognosis in renal cell carcinomaCancer, 1995
- In vivo Distribution of Integrins in Renal Cell Carcinoma: Integrin-Phenotype Alteration in Different Degrees of Tumor Differentiation and VLA-2 Involvement in Tumor MetastasisCancer Biotherapy, 1995
- Soluble ICAM-1 in Hodgkin's Disease: A Promising Independent Predicitive Marker for SurvialLeukemia & Lymphoma, 1995
- Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: Frequency and prognostic significanceEuropean Journal Of Cancer, 1994
- CD54/ICAM-1 Is a Costimulator of NK Cell-Mediated CytotoxicityCellular Immunology, 1994
- Signaling by lymphocyte function-associated antigen 1 (LFA-1) in B cells: enhanced antigen presentation after stimulation through LFA-1.The Journal of Experimental Medicine, 1992
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Functional evidence that intercellular adhesion molecule‐1 (icam‐1) is a ligand for lfa‐1d‐ependent adhesion in t cell‐mediated cytotoxicityEuropean Journal of Immunology, 1988